source
- Biogen sees continued revenue growth and pipeline readouts, M&A not essential, CEO saysBiogen reported third‑quarter earnings, marking a third straight quarter of revenue growth driven by its marketed products. The increase stemmed from higher sales of the Alzheimer’s therapy Leqemb…
- FDA drafts guidance to speed approvals of individualized gene therapies, hailed as win for rare disease patientsThe U.S. Food and Drug Administration released draft guidance aimed at streamlining the approval process for certain individualized gene therapies. The proposal would allow sponsors to avoid filing…